Key Takeaways:
- Zephyr has University of Salford independent acoustic data (n=30, all p < 0.001); SAM MS has no equivalent independently published acoustic testing available
- Zephyr uses fingertip variable airflow control and single-use sterile packs; SAM MS uses traditional suction control with reusable components requiring decontamination
- Zephyr holds CE Mark / UKCA Class II approval for all surgical suction applications; SAM MS is approved for cerumen removal only
- SAM MS offers battery-powered portability for domiciliary visits; Zephyr is mains-powered, ensuring consistent suction throughout a full clinic day
For audiologists and practice owners evaluating portable microsuction equipment, the decision often comes down to a small number of devices designed specifically for clinic-based ear wax removal. The SAM MS from SAM Medical and the Zephyr from Spoke Medical both target this market, but they take fundamentally different approaches to device design, noise management, and clinical evidence.
This article compares what is publicly known about each device, identifies where data is available and where it is not, and outlines the questions clinicians should ask before making a purchasing decision.
Overview of Each Device
SAM MS (SAM Medical)
The SAM MS is a battery-powered portable microsuction device used by private audiology practices across the UK. It is designed for cerumen removal in clinic and domiciliary settings. The device uses a traditional suction approach with a portable form factor.
Zephyr (Spoke Medical)
The Zephyr is a portable microsuction device engineered with noise reduction as a primary design objective. It features fingertip variable airflow control, patented anti-block technology, and single-use sterile consumable packs. It holds CE Mark and UKCA Class II approval for all surgical suction applications, including but not limited to cerumen management.
Head-to-Head Comparison
| Feature | SAM MS | Zephyr |
|---|---|---|
| Independent acoustic testing | No independently published data available | University of Salford, n=30, hemi-anechoic chamber |
| Overall noise (LAeq) | Not independently verified | 93.4 dB (vs 118.3 dB traditional) |
| Startup noise | Not independently verified | 65.0 dB |
| Idle noise | Not independently verified | 0 dB (no motor running when idle) |
| Active suction noise | Not independently verified | 95.2 dB |
| Peak LAmax | Not independently verified | 114.1 dB |
| Suction control | Traditional approach | Fingertip variable airflow control |
| Anti-block technology | Not specified | Yes (patented) |
| Infection control | Reusable components requiring decontamination | Single-use sterile packs |
| Power source | Battery-powered | Mains-powered |
| Portability | Yes (battery operation) | Yes |
| Regulatory approval | Medical device (cerumen removal) | CE Mark / UKCA Class II (all surgical suction) |
| ENT UK 2024 compliance | Not publicly documented | Compliant |
| Approval scope | Cerumen management | All surgical suction applications |
| Manufacturing standard | Not publicly documented | ISO 13485 |
The Acoustic Data Question
This is the most significant differentiator between the two devices, and it is not about which device is quieter in practice. It is about which device has independently verified acoustic data to support its claims.
The Zephyr has been tested by the University of Salford Acoustics Calibration Laboratory across 30 procedures, with measurements taken at 1/32-second precision across three distinct procedure phases (startup, idle, and active suction). The results are published and show statistically significant noise reduction at every phase, with all comparisons reaching p < 0.001 via Welch t-tests.
For the SAM MS, no equivalent independently published acoustic data is readily available. This does not mean the device is necessarily loud. It means that clinicians evaluating noise performance have verified data for one device and not for the other. In a clinical environment where noise-induced hearing damage is a recognised risk and ENT UK 2024 guidance specifically addresses noise safety, the availability of independent evidence matters.
Suction Control
The way suction intensity is managed during a procedure affects both clinical precision and patient comfort.
The SAM MS uses a traditional suction control approach. The clinician adjusts suction settings before or during the procedure using conventional mechanisms.
The Zephyr features fingertip variable airflow control integrated into the handpiece. This allows real-time modulation of suction intensity without removing the instrument from the working position or reaching for a separate control. This is particularly valuable when working near the tympanic membrane, managing sensitive ears, or transitioning between different wax consistencies within a single procedure.
Infection Control
Infection control protocols represent both a clinical and an operational cost consideration.
The SAM MS uses reusable components that require decontamination between patients. This involves cleaning, disinfection, and validation processes that consume staff time and materials. It also introduces a non-zero risk of cross-contamination if decontamination protocols are not followed correctly.
The Zephyr uses single-use sterile packs. Each patient receives a fresh, factory-sealed consumable set. This eliminates decontamination requirements for the suction pathway, reduces staff time between procedures, and provides an auditable chain of sterility for each patient encounter. The trade-off is an ongoing consumable cost, though this must be weighed against the staff time and materials saved by eliminating decontamination.
Regulatory and Approval Scope
Both devices hold medical device approval, but the scope of that approval differs.
The SAM MS is approved for use in cerumen removal. It is designed and marketed for audiology-focused microsuction.
The Zephyr holds CE Mark and UKCA Class II approval for all surgical suction applications. This means it is not limited to ear wax removal. Clinics that expand their scope of practice or that perform procedures beyond cerumen management can use the same device across a wider range of clinical applications. For practice owners considering future growth, this broader regulatory scope provides flexibility without additional equipment investment.
ENT UK 2024 Compliance
The ENT UK 2024 guidance on microsuction establishes expectations for noise management, patient safety, and equipment standards. The Zephyr’s independently verified acoustic performance demonstrates compliance with these recommendations.
For the SAM MS, public documentation confirming alignment with ENT UK 2024 guidance is not readily available. Clinicians using any device should be prepared to demonstrate how their equipment choice aligns with current professional guidance, particularly in the event of a patient complaint or regulatory inspection.
Battery vs Mains Power
The SAM MS operates on battery power, which offers genuine portability advantages for domiciliary visits where mains power may not be readily available. This is a practical strength for mobile audiology services.
The Zephyr is mains-powered, which ensures consistent suction performance throughout a full clinic day without concern for battery depletion mid-procedure. For fixed clinic settings, this is typically preferred. For domiciliary services, access to a power outlet is required.
Clinicians whose practice model relies heavily on home visits should consider power requirements as part of their evaluation.
What to Ask Before Choosing
When evaluating either device, or any microsuction equipment, audiologists and practice owners should ask the following:
- Is there independent acoustic data? Ask for published test results from an accredited laboratory, not just manufacturer claims.
- What are the noise levels at each procedure phase? Average figures can mask dangerous startup or peak noise spikes.
- How is suction controlled? Can you adjust intensity in real time without stopping the procedure?
- What is the infection control approach? Understand both the clinical and operational cost implications.
- What is the regulatory approval scope? Does the approval cover only cerumen removal, or does it extend to broader surgical suction?
- Is there alignment with ENT UK 2024 guidance? Can the manufacturer provide documentation?
- What is the total cost of ownership? Include consumables, decontamination costs, maintenance, and time savings in your calculation.
- What clinical advisory support exists? Does the manufacturer have clinical advisors who can support your practice?
Making an Informed Decision
Both the SAM MS and the Zephyr serve the portable microsuction market, but they represent different approaches to the same clinical challenge. The SAM MS offers battery-powered portability with a traditional suction approach. The Zephyr offers independently verified noise reduction, fingertip variable airflow control, anti-block technology, and single-use sterile consumables within a broader regulatory approval.
For clinicians who prioritise evidence-based equipment selection, the presence or absence of independent acoustic data is likely to be the deciding factor. In a market where noise-induced hearing damage is a recognised risk and professional guidance increasingly addresses equipment noise, the ability to point to verified, published performance data provides both clinical confidence and medicolegal protection.